ERBB2 and breast carcinoma: In the group of 397 patients with a median follow up of 10.4 years, the association between HER2 and anthracycline dose was even stronger than reported in the initial analysis, though this dose-response relationship in HER2+ breast cancer did not appear to hold for doses of doxorubicin above 60 mg/m2.